ClinicalTrials.gov lists 4 registered trials of ACE-031: 0 recruiting or about to, 0 running, 2 completed, 1 with results posted. The largest is A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women (70 people).
4registered trials
0recruiting now
0running
2completed
0in phase 3
1with results posted
Registered trials by phase. Phase 3 trials are the large ones that decide approval.
Each bar runs from a trial's start to its planned end; faded bars have no end date. Click a bar to open the trial.
Studying: Muscular Atrophy · NCT00952887
The purpose of this study is to establish safe dose levels of ACE-031 in healthy postmenopausal women following multiple dose administration. This study will also evaluate if ACE-031 has an effect on muscle.
Studying: Muscle Loss · NCT00755638
Single center, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of ACE-031 in healthy postmenopausal volunteers
Studying: Duchenne Muscular Dystrophy · NCT01239758
To evaluate the long-term safety and tolerability of ACE-031 administration in subjects with Duchenne muscular dystrophy (DMD) who participated in Study A031-03. \[Note: This study was terminated based on preliminary safety data. Pending further analysis of safety data and discussion with health authorities, a new ACE-031 trial will be planned.\]
Studying: Duchenne Muscular Dystrophy · NCT01099761
The purpose of this study is to determine if ACE-031 is safe and well-tolerated in boys with Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of safety and pharmacodynamic (PD) activity for designing future studies. \[Note: This study was terminated based on safety data\]
Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (ACE-031, ActRIIB-Fc, ramatercept) in the listed interventions.